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The patient initially presented with gum bleeding and a petechial rash.  
 
Diagnosis 
The patient was found to be severely thrombocytopaenic and bone marrow biopsy showed a marked 
excess of megakaryocytes consistent with a diagnosis of immune thrombocytopaenia (ITP). She 
underwent splenectomy. Seven years following splenectomy, her platelet count began to rise again, 
and repeat bone marrow sampling revealed an increase in megakaryocytes with evidence of 
clustering. On further testing the calreticulin (CALR) exon 9 variant was found and a diagnosis of 
essential thrombocythaemia (ET) was made. 
 
Treatment 
Thromboprophylaxis and cytoreductive therapy (hydroxyurea) were initiated following ET diagnosis. 
 
Discussion 
Possible mechanisms of ET (platelet excess) following ITP (platelet deficiency) include the known 
associations of autoimmune conditions and malignancy and the effects of immunosuppression and 
splenectomy in tumorigenesis. To our knowledge, this is the first recorded case of ITP preceding later 




ITP is an autoimmune condition characterised by peripheral destruction of platelets.1 ET is one of the 
myeloproliferative neoplasms (MPNs) and is characterised by overproduction of platelets, leading to 
increased risk of thrombosis. Greater than 95% of ET cases are associated with the Janus kinase (JAK)-
2, CALR or myeloproliferative leukaemia virus oncogene (MPL) gene mutations.2 
Case Report 
A 57-year-old female presented in 2004 with a history of gum bleeding and a petechial rash on a 
background of hypothyroidism. A full blood count (FBC) performed by her General Practitioner 
revealed a platelet count of 20 x109/l with a haemoglobin (Hb) of 147g/l and white cell count (WCC) 
of 7.9 x109/l. Her blood film showed thrombocytopaenia only and her renal and liver function were 
within normal limits. Her coagulation, serum protein electrophoresis, haematinic, virology and 
autoimmune screen were normal. Lactate dehydrogenase (LDH) levels were elevated at 596 units/l 
(normal value 220-450 units/l). Bone marrow biopsy showed a marked excess of megakaryocytes 
consistent with a diagnosis of ITP. She was commenced on high-dose prednisolone therapy which led 
to rapid normalisation of her platelet count. Following steroid withdrawal, she relapsed and was 
referred for splenectomy. Postoperatively she had a significant rebound thrombocytosis with a 
platelet count increase to 1237 x109/l. Repeat bone marrow sampling showed normal megakaryocytes 
and increased erythropoiesis consistent with a recovering marrow.  
Seven years following splenectomy, her platelet count began to rise (see figure 1). JAK-2 mutational 
analysis was negative. She was initially started on aspirin but following development of paroxysmal 
atrial fibrillation (PAF) this was switched to apixaban. Repeat bone marrow sampling following an 
episode of significant haematoma in her thigh showed an increase in megakaryocytes with evidence 
of clustering. The CALR exon 9 variant was found, confirming a diagnosis of ET. Cytoreductive therapy 
(hydroxycarbamide) has been commenced. 
 
 
Figure 1: Changes in platelet count during disease course. 
 
Discussion 
To our knowledge, this is the first time a patient has developed ET caused by the CALR mutation 
following initial ITP diagnosis. Three patients have previously been described with initial ITP and then 
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A prior history of any autoimmune disease has been shown to be associated with an increased risk of 
MPN (odds ratio (OR)=1.2; P=0.021).6 It is likely that the chronic inflammatory state inherent in an 
autoimmune condition could contribute to tumorigenesis and thus provoke an MPN. Also, use of 
multiple immunosuppressants could allow a clone to escape apoptosis and promote malignancy 
(although less likely in our case, where the patient proceeded relatively rapidly to splenectomy). 
Finally, there may be a shared genetic susceptibility with autoimmune conditions and cancer that 
renders an individual predisposed to the development of both. 
It is possible that splenectomy, when performed for ITP, may unmask ET by removing the function of 
the spleen in immune-mediated cellular destruction.4 ET has been seen post-splenectomy for non-ITP 
causes in patients with initially normal blood counts.7,8,9 
A key challenge for these patients concerns the diagnosis and management of cytopaenias in the 
context of both cytoreductive therapy and the potential relapse of ITP. A suggested approach to this 
is to withhold cytoreductive therapy and treat with immunosuppression, prior to restarting 
cytoreduction once the platelet count reaches an appropriate threshold.  
In summary, this is to our knowledge the first recorded case of ITP preceding later development of 
CALR- positive ET and is illustrative of the complexities of management of patients with concurrent 
haematological diagnoses. 
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